Sector: Health Care
Director information for BIO TECHNE CORP (data for year 2025)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Alpna Seth | Chair | [] | [] | 2025 | |
| Alpna Seth, Ph.D. | Former President and CEO, Nura Bio Inc. | 62 | ["Retired as President and Chief Executive Officer of Nura Bio Inc.", "Former Chief Operating Officer of Vir Biotechnology, Inc.", "Nearly two decades at Biogen Inc.", "Senior Vice President and global head of the Biosimilars business at Biogen", "Experience leading major drug development programs and product launches", "Background in international operations and business development", "Ph.D. in Biochemistry and Molecular Biology from University of Massachusetts Medical School", "Post-doctoral research at Harvard University", "Graduated from Harvard Business School\u2019s Advanced Management Program"] | ["Nominations and Governance", "Science and Technology"] | 2025 |
| Amy E. Herr, Ph.D. | Professor, University of California, Berkeley | 50 | [] | [] | 2025 |
| Amy Herr | ["Industry Background", "Scientific/Technical Expertise"] | ["Science and Technology Committee"] | 2025 | ||
| Amy Herr, Ph.D. | Vice President | 50 | ["Chancellor\u2019s Professor of Bioengineering at the University of California, Berkeley", "Vice President of the Chan Zuckerberg Biohub Network", "Founding Executive Director of UC Berkeley\u2019s Bakar BioEnginuity Hub", "Served on the National Advisory Council for Biomedical Imaging and Bioengineering (NACBIB)", "Served on several governmental science advisory boards", "Ph.D. in Mechanical Engineering from Stanford University", "Bachelor of Science in Engineering & Applied Science from Caltech", "Experience as a researcher, academician, scientific advisor, and leader in bioengineering", "Expertise in the application of AI tools in science"] | ["Science and Technology"] | 2025 |
| Dr. Amy Herr | Board Member | [] | [] | 2025 | |
| Dr. Roeland Nusse | Board Member | [] | [] | 2025 | |
| Dr. Rupert Vessey | Executive Partner and Chief Scientist | 60 | ["Exceptional background in medical and life science research and development", "Experience with Bristol-Myers Squibb, Celgene, Merck", "Extensive experience as an executive in the pharmaceutical industry", "International research and business experience"] | ["Science and Technology", "Compensation"] | 2025 |
| John L. Higgins | Former President and CEO, Ligand Pharmaceuticals; Director; Chair | 55 | ["Over 20 years of industry experience", "Chief Executive Officer of Ligand Pharmaceuticals", "Leadership roles in other pharmaceutical companies", "Experience in strategic leadership within the industry", "Broad public company executive and board experience", "Extensive financial background"] | ["Audit", "Nominations and Governance"] | 2025 |
| Joseph D. Keegan | [] | [] | 2025 | ||
| Joseph D. Keegan, Ph.D. | Advisor and Board Director | 72 | ["Director and advisor for Interpace Diagnostics", "Former President and Chief Executive Officer of ForteBio, Inc.", "Former President and Chief Executive Officer of Molecular Devices Corporation", "Held leadership positions at Becton Dickinson, Leica, Inc., and GE Medical Systems", "Executive Chair of Halo Labs and Carterra", "Non-Executive Chairman for Arrayjet", "Director for Nuclera and Biolog", "Ph.D. in Physical Chemistry, Stanford University"] | ["Compensation", "Nominations and Governance"] | 2025 |
| Judith Klimovsky | [] | [] | 2025 | ||
| Judith Klimovsky, M.D. | Executive Vice President and Chief Development Officer, Genmab, Inc. | 68 | ["strong medical and scientific foundational training", "experience leading product development and commercial life cycle management", "proven success in cultivating growth through innovation", "deep knowledge of the global pharmaceutical and biotechnology industries"] | ["Nominations and Governance", "Science and Technology"] | 2025 |
| Julie L. Bushman | Former EVP International Operations, 3M; Director; Chair | 64 | ["Retired from 3M Corporation as Executive Vice President of International Operations", "Joined 3M in 1983 and served in various executive positions", "Extensive global experience managing international operations", "Broad digital, software, and CIO experience", "Valuable governance experience through service on two public company boards"] | ["Audit", "Compensation"] | 2025 |
| Kim Kelderman | President and CEO, Bio-Techne Corporation | 58 | ["Critical insight on Bio-Techne\u2019s commercial business", "Day-to-day operations management", "Extensive executive management experience", "Expertise leading the growth of biotechnology companies"] | [] | 2025 |
| Robert V. Baumgartner | Former Executive Chairman, Center for Diagnostic Imaging; Independent Chair of the Board | 69 | ["20 years serving as Chief Executive Officer and Executive Chairman of large, complex businesses", "extensive experience in finance, accounting, and business leadership", "important board-level experience", "knowledge of Bio-Techne\u2019s business and industry", "sets the agenda for Board meetings", "presides over executive sessions of the independent directors", "presides over meetings of the full Board", "executes the Board\u2019s direction", "serves on the Board and invited to all committee meetings", "responsible for the day-to-day leadership and performance of the Company"] | ["Audit", "Compensation"] | 2025 |
| Rupert Vessey | Chair | [] | [] | 2025 | |
| Rupert Vessey, MA, BM BCh, FRCP, DPhil | Executive Partner and Chief Scientist, Flagship Pioneering, Inc. | 60 | [] | [] | 2025 |
